- Home
- FIVE vs ROIV Comparison
FIVE vs ROIV Comparison
Compare FIVE & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FIVE
- ROIV
- Stock Information
- Founded
- FIVE 2002
- ROIV 2014
- Country
- FIVE United States
- ROIV United Kingdom
- Employees
- FIVE N/A
- ROIV N/A
- Industry
- FIVE Department/Specialty Retail Stores
- ROIV Biotechnology: Pharmaceutical Preparations
- Sector
- FIVE Consumer Discretionary
- ROIV Health Care
- Exchange
- FIVE Nasdaq
- ROIV Nasdaq
- Market Cap
- FIVE 7.1B
- ROIV 7.8B
- IPO Year
- FIVE 2012
- ROIV N/A
- Fundamental
- Price
- FIVE $132.54
- ROIV $10.99
- Analyst Decision
- FIVE Buy
- ROIV Buy
- Analyst Count
- FIVE 19
- ROIV 4
- Target Price
- FIVE $115.94
- ROIV $17.50
- AVG Volume (30 Days)
- FIVE 1.5M
- ROIV 7.2M
- Earning Date
- FIVE 08-27-2025
- ROIV 08-07-2025
- Dividend Yield
- FIVE N/A
- ROIV N/A
- EPS Growth
- FIVE N/A
- ROIV N/A
- EPS
- FIVE 4.78
- ROIV N/A
- Revenue
- FIVE $4,035,191,000.00
- ROIV $29,053,000.00
- Revenue This Year
- FIVE $16.13
- ROIV $2.64
- Revenue Next Year
- FIVE $9.97
- ROIV $378.09
- P/E Ratio
- FIVE $27.48
- ROIV N/A
- Revenue Growth
- FIVE 10.71
- ROIV N/A
- 52 Week Low
- FIVE $52.38
- ROIV $8.73
- 52 Week High
- FIVE $137.30
- ROIV $13.06
- Technical
- Relative Strength Index (RSI)
- FIVE 69.78
- ROIV 44.89
- Support Level
- FIVE $128.53
- ROIV $10.83
- Resistance Level
- FIVE $134.32
- ROIV $11.82
- Average True Range (ATR)
- FIVE 3.78
- ROIV 0.32
- MACD
- FIVE -0.49
- ROIV -0.07
- Stochastic Oscillator
- FIVE 86.53
- ROIV 16.75
About FIVE Five Below Inc.
Five Below Inc is a specialty value retailer offering merchandise targeted at the tween and teen demographic. The Company's edited assortment of products includes select brands and licensed merchandise. It derives revenue from sales of the Company's merchandise to customers.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.